Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 11 results found. Search for [ Covishield vs ]

Results 1 to 11 of 11
BusinessToday.In
April 26, 2021
The move comes days ahead of the third phase of India's COVID-19 vaccination programme in the backdrop of criticism over prices of Covaxin and Covishield for states and private players


BusinessToday.In
April 24, 2021
At these rates, Covaxin will be twice as costly as Covishield, which will be sold to state governments at Rs 400 per dose and to private hospitals at Rs 600 per dose in Phase 3 of vacccination drive


PB Jayakumar
March 15, 2021
The original ACT-Accelerator investment case published in September 2020 had outlined a total requirement of US$ 38.1 billion to fully fund its work for 2020-21, but so far could mobilise only US$11 billion


BusinessToday.In
March 4, 2021
Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus


Joe C Mathew
March 3, 2021
The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR


BusinessToday.In
March 3, 2021
Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India


BusinessToday.In
March 2, 2021
As senior citizens across the country take part in the vaccination drive, here is all the information they need two know about the two vaccines - Covaxin and Covishield


BusinessToday.In
January 12, 2021
The two vaccines - Covishield and Covaxin - have received regulatory approval after extensive studies. The Covishield  vaccine has already been rolled out in the UK


BusinessToday.In
January 12, 2021
Coronavirus vaccination: We have given a special price of Rs 200 for the first 100 million doses only to the Government of India on their request that we want to support the common man, vulnerable, poor and healthcare workers, said Poonawalla


Rajeev Dubey
New Delhi, January 5, 2021
Dr Krishna Ella, Bharat Biotech chairman spoke to Business Today editor Rajeev Dubey about the efficacy of Covaxin and what makes it safe for use. He said his vaccine was stable and they had data for four months to substantiate the claim. Watch the video for more.


BusinessToday.In
December 7, 2020
Anurag Kashyap and Anil Kapoor engaged in an ugly fight on Twitter and questioned each other's careers. Anil Kapoor wrote, \"#neverforget Bombay velvet Box Office Returns = 43 Crore. Race 3 Box Office Returns = 300 Crore\"


PAGES 1 OF 1